Cart
sales@molnova.com
PCSK9-IN-10
PCSK9-IN-10
Catalog No. M36396
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 μM.
| Size | Price / USD | Stock | Quantity |
| 2MG | 62 | Get Quote |
|
| 5MG | 92 | Get Quote |
|
| 10MG | 147 | Get Quote |
|
| 25MG | 288 | Get Quote |
|
| 50MG | 454 | Get Quote |
|
| 100MG | 653 | Get Quote |
|
| 500MG | 1368 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePCSK9-IN-10
-
Brief Description
-
Description
-
Storage
-
NoteResearch use only, not for human use.
-
Reference1. Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047.?
molnova catalog
related products
-
SPHINX31
SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50: 5.9 nM).
-
CID-2011756
CID-2011756 is a cell-active ATP competitive and specific PKD1 inhibitor that inhibits phorbol ester-induced endogenous PKD1 activation in LNCaP prostate Y cells.
-
IPR-803
IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM.
